anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a composition exhibiting bone mass increasing effect on growing child and preventing or improving effect on bone diseases other than osteoporosis, e.g. bone destruction caused by rheumatoid arthritis or bone metastasis of cancer in addition to the prevention of osteoporosis of aged person, and provide drinks, foods, supplements, etc., containing the composition.  <P>SOLUTION: It has been found that the administration of Sudachi (Citrus sudachi hort. ex Shirai) juice to a spayed mouse known as an osteoporosis model animal significantly lowers the bone loss, keeps the body weight, does not increase the weight of uterus contracted by spaying and is a safe agent free from unadvantageous action to the total body. Accordingly, the Sudachi juice is found to be effective for the prevention/treatment of osteoporosis.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The invention discloses construction and application of engineering bacteria for expressing a plant antibacterial peptide Ct-AMP1, wherein an amino acid sequence of the plant antibacterial peptide Ct-AMP1 fusion protein is shown as SEQ ID No. 1. The coding gene sequence is shown in SEQ ID No. 2. The protein of the invention has obvious treatment and regulation effects on escherichia coli, staphylococcus aureus, salmonella, pseudomonas aeruginosa and candida albicans. The cationic polypeptide compound expressed by the food-grade bacillus subtilis directly inhibits and kills escherichia coli, staphylococcus aureus, salmonella, pseudomonas aeruginosa and candida albicans through electrostatic combination. Repairing intestinal mucosa injury caused by bacterial infection.
MAC Project is a prospective cohort, multicenter, observational, no-profit study aimed to prospectively collect reliable real-life clinical information in unselected VTE or NVAF patients treated with any DOAC, during a medium-long term follow-up period. Patients will be investigated in Italian hospital-based clinical centers, skilled in the management of adult patients with VTE or NVAF requiring anticoagulant treatment, and followed-up up to 5 years. The drugs will be prescribed according to current standards of care and regulations and not provided by any sponsor. The primary outcome is to collect and evaluate the safety and efficacy data of DOACs in a real-life setting, regardless of the underlying pathology, and the duration of treatment. The secondary outcome is to separately evaluate safety and efficacy of DOACs for treatment of cardiovascular diseases, specifically considering treatment duration, as follows: short-term (e.g., superficial venous thrombosis); medium-term (e.g., deep vein thrombosis, pulmonary embolism, etc.); long-term (e.g., atrial fibrillation, prevention of recurrent VTE or long-term treatment of recurrent VTE, peripheral arterial obstructive disease, etc.).Investigators will store event-driven clinical information into a REDCap based on-line EDC system about management and outcome of all efficacy and safety end-points; treatment compliance/adherence; VTE risk factors; thromboembolic and haemorrhagic risk-scores; comorbidities; concomitant treatments; patients' appreciation by a specific score (ACTS); clinical or adverse events; survival; possible causes of death.
The present invention relates to high doses of macitentan (INN), i.e. propylsulfamic acid [5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl]-amide or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof for use in the treatment of pulmonary vascular disease and/or cardiac dysfunction in functional single ventricular heart disease patients, especially in Fontan-palliated patients. Moreover, the present invention relates to the use of high doses of macitentan for the manufacture of a medicament as well as to a method for the treatment of said diseases. Further, the present invention relates to a dosage regimen as well as to a combination of macitentan with one or more phosphodiesterase type 5 (PDE5) inhibitors, prostacyclin analogues, prostacyclin receptor agonists or soluble guanylate cyclase stimulators. Besides, the present invention relates to a pharmaceutical composition for the treatment of pulmonary vascular disease and/or cardiac dysfunction in functional single ventricular heart disease patients, especially in Fontan-palliated patients comprising a high dose of macitentan. Moreover, the present invention relates to the use of high doses aprocitentan for the same purpose.
The present invention provides use of phenylquinolinone deriviative or flavonoid derivative for neuropathic pain. Also, The phenylquinolinone deriviative or flavonoid derivative comprise of their pharmaceutically acceptable salts thereof. The compound of the present invention is a histamine H3 receptor antagonist, has a different mechanism of action from existing drugs, and can be used in the preparation of drugs for treating neuropathic pain diseases. The effect of the compound of the present invention for treating neuropathic pain is superior to that of amitriptyline, gabapentin, pregabalin and carbamazepine. Therefore, the compound of the present invention has a better treatment effect, and has the characteristics of a small dosage, good drug efficacy, high bioavailability and high safety. Compared with opioids, the compound of the present invention has no addiction property, and is a very effective drug for treating neuropathic pain diseases. Therefore, the compound has a great prospect in clinical application. The phenylquinolinone deriviative or flavonoid deriviative has a general structural formula is as following: (I)
PURPOSE:To obviate the dissipation before and after packing to the defect part of a bone and to improve the fixability between granules by constituting the glue of an aq. sol. contg. >=1 kinds selected from plurane, glycol chitin, carboxymethyl chitin, and pectin which are dissolved in water. CONSTITUTION:The high-viscosity soln. having tacky adhesiveness is produced when >=1 kinds of the plurane, glycol chitin, carboxymethyl chitin, and pectin are dissolved in water. These materials are dissolved into the water at such ratios at which the aq. soln. has >=1000cps viscosity at room temp. The above- mentioned compd. does not generate a harmful effect in the living body and, therefore, this glue has high safety. The glue is produced simply by subjecting the above-mentioned compsn. to high-pressure steam sterilization first, then dissolving the compd. into distilled water subjected to sterilization.
Replication-conditional plasmids which are useful for the Pasteurellaceae have been isolated and characterised. The plasmids can be utilized for delivery of DNA segments into the Pasteurellaceae in situations where control of extrachromosomal replication desired, such as in achieving allelic exchange or site-directed mutagenesis. A restriction endonuclease, HsoI, was isolated from a bovine lung isolate of Haemophilus somnus. The enzyme was found to be a true isoschizomer of HinPI, a commercially available enzyme originally isolated from Haemophilus influenzae PI. Commercially available HhaI methyl transferase was found to protect against cleavage by both enzymes. Methylation of foreign plasmid DNA was found to enhance transformation of Haemophilus somnus in excess of four orders of magnitude. The replication-conditional plasmid is useful for the production of live, attenuated vaccine production against respiratory disease syndrome in domestic cattle caused by Pasteurella haemolytica, Pasteurella multocida and Haemophilus somnus.
BACKGROUND: The purpose of our study was to determine the frequency and management of intrathyroidal parathyroid glands in patients with primary hyperparathyroidism and evaluate whether intrathyroidal parathyroid glands were more often superior or inferior glands.
METHODS: A retrospective review of the prospective parathyroid database was completed to determine the number of patients with primary hyperparathyroidism and an intrathyroidal parathyroid gland. Demographic data, laboratory and localization studies, operative management, pathology, and outcome were determined for patients with an intrathyroidal parathyroid gland and were compared with patients with an extrathyroidal parathyroid gland.
RESULTS: From 1990-2023, 808 patients were operated on for primary hyperparathyroidism; 17 (2%) patients had an intrathyroidal parathyroid gland, an adenoma in 15 (88.2%), and a hyperplastic gland in 2 (11.8%). The mean age was 53 years; 16 (94%) patients were female. Mean calcium and parathyroid hormone was 12 mg/dL and 150 pg/mL, and there were no differences from the extrathyroidal parathyroid group. Ultrasound and Sestamibi imaging were valuable in identifying an intrathyroidal parathyroid gland in 10 of 13 patients and 13 of 17 patients, respectively. Local excision was performed in 9 (53%) patients and lobectomy in 8 (47%) patients. Intraoperative parathyroid hormone was measured and predictive of cure in 12 patients. The location of intrathyroidal parathyroid glands was determined in 15 patients and was inferior in 11 (73%). All patients were cured. No patient developed recurrent disease after a median 54-month follow-up.
CONCLUSION: Intrathyroidal parathyroid glands are the cause of primary hyperparathyroidism in 2% of patients and are most often inferior glands. Local excision was accomplished in 53% of our patients.
The present invention relates to a method of synthesis of compounds, i.e. mono-protected dimeric bifunctional prodrugs based on duocarmycin analogs, for the preparation of Antibody Drug Conjugates (ADCs). In another aspect, there is provided a compound obtained by the process according to the invention. The mono-protected bifunctional prodrugs are useful for preparing antibody drug conjugates consisting of an antibody moiety and a mono-protected bifunctional prodrug. Antibody compound conjugates thus obtained are provided. Furthermore, a method of preparing an antibody drug conjugate consisting of two identical or two different antibody moieties is provided, as well as antibody compound conjugates comprising two different antibody moieties accordingly. These conjugates can be used in pharmaceutical compositions, in particular for the treatment of tumors, e.g. for ADC therapy.
Over the past decade, the use of frozen-thawed embryo transfer (FET) has risen around the globe. There is no consensus which mode of FET is superior, either natural cycle (NC) or artificial cycle (AC) with hormonal replacement therapy (HRT). The latter has become more and more popular because it allows more flexibility in timing of FET and it requires fewer visits for monitoring before the transfer. AC also has the advantage of a more precise control of progesterone (P) exposure, which is of utmost importance for controlling the window of implantation between the embryo and the endometrium. Although FET in AC give excellent results, there is still a need for improvement, as the ideal dose is not individualized to a patient's characteristics and serum P required for optimal cycle outcome haven't been established.

Retrospective studies about P levels on the day of FET in AC cycles showed contradictory results regarding cycle outcomes. Several studies showed that a lower P levels on FET day, or one day prior, are associated with lower clinical pregnancy rate (CPR) or live birth rate (LBR), whereas one study showed that women with higher P on FET day were having lower LBRs. Recently, a prospective study showed that serum P level \< 9.2 ng/ml on the day of FET in oocyte reception cycles was associated with a significant lower ongoing pregnancy rate. Considering these previous studies, we wanted to determine if different serum P levels on FET day are associated with different CPR, and if increasing dosage of vaginal P in cases of lower serum P level on FET day can be either beneficial or detrimental.
The invention provides vanilla extract for activating organism immunity and a preparing method and application thereof. The vanilla extract is composed of vanilla essential oil and vanilla distillate. Vanilla varieties comprise eupatorium fortunei, menthapiperita and cymbopogon citratus. The vanilla essential oil and the vanilla distillate are obtained by distilling fresh blades of eupatorium fortunei, menthapiperita and cymbopogon citratus through steam. The vanilla extract for activating the organism immunity can be added into beverages to manufacture vanilla distillate drinks, or added into soap bases to manufacture vanilla health soap, or added into cosmetic matrix to manufacture emulsion and cream. The effective ingredients of the extract are compounded according to different vanilla essential oil characteristic aroma components and effect optimization, and active ingredients, nutritious ingredients and aroma ingredients contained in the vanilla extract have a synergistic effect and are beneficial for activating the organism immunity. The vanilla extract is applied to the beverages, the soap bases or skincare products and can promote and maintain organism health.
Fentanyl transdermal system is supplied in sealed transdermal systems which pose little risk of exposure to health care workers. Do not use a fentanyl transdermal system patch if the pouch seal is broken or the patch is cut, damaged, or changed in any way.

KEEP FENTANYL TRANSDERMAL SYSTEM OUT OF THE REACH OF CHILDREN AND PETS.

Store in original unopened pouch. Store up to 25°C (77°F); excursions permitted to 15 – 30°C (59 – 86°F). Apply immediately after removal from individually sealed pouch. Do not use if the pouch seal is broken. For transdermal use only.
The probiotic chewing gum should be chewed on for about 10 minutes. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
PURPOSE OF REVIEW: Epithelial ovarian cancer (EOC) is the fifth cause of cancer death among women, and 70-80% of patients relapse within 2 years from the last cycle of first-line chemotherapy despite a complete response to chemotherapy and optimal debulking surgery. In this context, the goal of the maintenance treatment strategy is to prolong the time to recurrence. The recent development of targeted molecular therapies resulted in a broader spectrum of maintenance therapeutic options with consequent higher clinical benefit but less toxicity. This review summarizes the currently available maintenance strategies for newly and recurrent EOC, focusing on the decision-making process to personalize treatment and future perspectives.
RECENT FINDINGS: Over the past 10 years, several studies have demonstrated the clear benefit in terms of survival with the addition of a maintenance treatment strategy over the 'watchful waiting' approach both in the first line and recurrent setting. Since December 2016, the United States Food and Drug Administration and European Medicines Agency have approved four drugs for ovarian cancer maintenance based on the results of several clinical trials demonstrating efficacy and tolerability. These include the antiangiogenic drug Bevacizumab and three polyadenosine diphosphate-ribose polymerase (PARP) inhibitors: olaparib, niraparib, and rucaparib.
SUMMARY: These data led American and European Treatment guidelines to include bevacizumab, olaparib, niraparib, rucaparib, and combination bevacizumab-olaparib as maintenance treatment options in first-line and recurrent ovarian cancer therapy. However, with the availability of different maintenance options, identifying the best treatment choice for each patient can be challenging, and several clinical and molecular aspects have to be taken into account in the decision-making process.
The study aims to design and optimize the floating formulations of the aqueous extract of Desmostachya bipinnata (ADB) to treat peptic ulcers. The trial concentrations of HPMC E50, HPMC K4M, and Carbopol 940 were used as factors, and floating lag time, total floating time, and % drug release at 12 h were used as responses. The formulation underwent evaluation for different parameters: aspirin-induced ulcers in rats assessed the antiulcer activity, and X-ray studies in rabbits evaluated the gastroretentive nature. The optimized formulation has shown a floating lag time of 32 s and floated in the gastric medium for more than 9 h with a maximum drug release of 93% at the end of 12 h by following the Korsmeyer-Peppas drug release mechanism. The optimized formulation has good flow properties. The FT-IR, DSC, and XRD studies show ADB and excipients didn't show any incompatibility. The formulation has shown significant antiulcer activity against aspirin-induced ulcers in rats, with an ulcer index of 3.38 ± 0.24 and inhibition of 76.67 ± 0.56%. The in vivo X-ray imaging proved the gastric retention of the formulations for more than 8 h. The results of the formulations demonstrate the floating ability and sustained drug release of the tablet responsible for treating peptic ulcers to show a localized effect in the gastric region and to maintain the ROS levels.
We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 1.5 whole eggs (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
Enalapril maleate oral solution is a ready-to-use solution that contains 1 mg/mL of enalapril maleate, USP. It is a clear, colorless oral solution with a mixed berry flavor, packaged in a 150 mL, white, round, high-density polyethylene bottle with a white, polypropylene, child-resistant cap and placed in a carton with tamper-evident seal. Each bottle contains 150 mL.

NDC 69452-237-46

Store refrigerated (2° to 8°C/36° to 46°F) in a tightly closed container. Protect from freezing and excessive heat. Patients may store enalapril maleate oral solution at room temperature (20° to 25°C/68° to 77°F) for up to 60 days.
Identifying genetic drivers of chronic diseases is necessary for drug discovery. Here, we develop a machine learning-assisted genetic priority score, which we call ML-GPS, that incorporates genetic associations with predicted disease phenotypes to enhance target discovery. First, we construct gradient boosting models to predict 112 chronic disease phecodes in the UK Biobank and analyze associations of predicted and observed phenotypes with common, rare, and ultra-rare variants to model the allelic series. We integrate these associations with existing evidence using gradient boosting with continuous feature encoding to construct ML-GPS, training it to predict drug indications in Open Targets and externally testing it in SIDER. We then generate ML-GPS predictions for 2,362,636 gene-phecode pairs. We find that the use of predicted phenotypes, which identify substantially more genetic associations than observed phenotypes across the allele frequency spectrum, significantly improves the performance of ML-GPS. ML-GPS increases coverage of drug targets, with the top 1% of all scores providing support for 15,077 gene-phecode pairs that previously had no support. ML-GPS can also identify well-known target-disease relationships, promising targets without indicated drugs, and targets for several drugs in clinical trials, including LRRK2 inhibitors for Parkinson's disease and olpasiran for cardiovascular disease.
Accelerated Brachytherapy Forward Chemo Radiation Therapy (ABC-RT) combines hypofractionated external beam radiation therapy (EBRT) with concurrent chemotherapy and early upfront, image-guided brachytherapy. In this study, patients start with 2 fractions of brachytherapy prior to initiation of EBRT-based chemoradiotherapy. Total time from treatment planning is approximately 36-42 days.
Pseudomonas aeruginosa  flagellin protein recruits the mammalian host sialidase enzyme neuraminidase- 1 (NEU1) to remove sialic acid residues from the extracellular domain of the mammalian cell-surface protein MUC l (MUC l -ED), thereby exposing a cryptic binding site on the MUC l -ED protein backbone for flagellin binding. NEU1 -driven MUC l -ED desialylation rapidly increases  P. aeruginosa  adhesion to the airway epithelium. MUCl -ED desialylation also increases MUC l -ED cleavage and shedding from the cell surface, where desialylated, shed MUCl -ED competitively blocks  P. aeruginosa  adhesion to cell-associated MUCl -ED. Presented herein are data showing that exogenously-administered, deglycosylated MUCl -ED peptides reduced adhesion of  P. aeruginosa  to airway epithelial cells. Also presented are data showing that administration of  P. aeruginosa  to mice in combination with deglycosylated MUC 1 -ED decreased  P. aeruginosa  recovered from the lungs at 48 hr and 72 hr post-infection. Such findings are extended to the methods of treatment and prevention of bacterial infections defined herein.
This study was planned to investigate the effect of back health education given to academicians on physical function and body awareness. The study was completed with a total of 94 (49 female and 45 male) volunteer academicians (intervention group n=47, control group n=47) between the ages of 25-65, with a mean age of 43.22±10.924 years. The participants of both groups were evaluated before and after the 6-week education and training. In order to evaluate physical functions of the participants, One Leg Standing Test (eyes open and closed), Half Squat Test, Curl-Up Test, and Sit and Reach Test were used. The Body Awareness Questionnaire (BAQ) was used to assess body awareness of the sample. The participants of the intervention group received back health education (Back School) in the classroom. After the education program, they participated in exercise training for six weeks (one day a week). The control group was only given an informative brochure on back health and asked to read it.
<P>PROBLEM TO BE SOLVED: To provide a method and composition useful for diagnosis of patients of scurfy-associated diseases.  <P>SOLUTION: The problem is solved by providing isolated nucleic acid molecules which encode Fkh<SP>sf</SP>, as well as mutant forms thereof. Also provided are expression vectors suitable for expressing such nucleic acid molecules, and host cells containing such expression vectors. Also provided are pharmaceutical compounds and methods of identifying such compounds that can modulate the immune system. In addition, are provided methods for identifying proteins regulated by Scurfin and proteins that induce or inhibit Foxp3 expression.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The prospective, randomized, controlled study involves the enrollment of cataract patients with corneal endothelial dysfunction. All the patients will be randomly assigned with equal probability to the following two groups: 1. Staged group: phacoemulsification + IOL implantation is performed individually and DMEK is performed secondarily according to the corneal status of patients. During cataract surgery, viscoelastic materials and anterior lens capsule are used to protect the compromised corneal endothelium during phacoemulsification. After phacoemulsification and removal of all the lens material, a one-piece foldable IOL is implanted into the lens capsule. 2: Combined group: phacoemulsification + IOL implantation and DMEK is performed simultaneously. Standard procedures of phacoemulsification + IOL implantation are the same as in the staged group.

Patients enrolled into the study will be followed for one year and will have study visits at 1 day, 1 week, 2 weeks, 1 month, 3 months, 6 months and 12 months after each surgery.